Gala­pa­gos snags co-pro­mo­tion rights on fil­go­tinib — just be­fore Gilead’s lock-up pact ex­pires

Ex­act­ly two years af­ter Gilead $GILD stepped in with $725 mil­lion in cash to buy in­to li­cens­ing rights for Gala­pa­gos’ $GLPG spot­light drug fil­go­tinib, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA